??-Blockers Drug Interactions of Clinical Significance

Blaufarb, Ira; Pfeifer, Tracy M.; Frishman, William H.

doi:10.2165/00002018-199513060-00005

Cited by 19 publications

(8 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some interactions are well-documented, whereas other potential interactions await further investigation (Rosenthal and Ezra, 1995). BABs may further interact with inotropic agents, anti-arrhythmics, NSAIDs, psychotropic drugs, anti-ulcer medications, statins, warfarin, and oral hyperglycamics (Blaufarb et al, 1995). In general, many potential interactions can be predicted with anti-arrhythmics, quinidine and amiodarone in particular.…”

Section: Discussionmentioning

confidence: 99%

Oral Adverse Drug Reactions to Cardiovascular Drugs

Torpet

Kragelund

Reibel

et al. 2004

Critical Reviews in Oral Biology & Medicine

View full text Add to dashboard Cite

A great many cardiovascular drugs (CVDs) have the potential to induce adverse reactions in the mouth. The prevalence of such reactions is not known, however, since many are asymptomatic and therefore are believed to go unreported. As more drugs are marketed and the population includes an increasing number of elderly, the number of drug prescriptions is also expected to increase. Accordingly, it can be predicted that the occurrence of adverse drug reactions (ADRs), including the oral ones (ODRs), will continue to increase. ODRs affect the oral mucous membrane, saliva production, and taste. The pathogenesis of these reactions, especially the mucosal ones, is largely unknown and appears to involve complex interactions among the drug in question, other medications, the patient's underlying disease, genetics, and life-style factors. Along this line, there is a growing interest in the association between pharmacogenetic polymorphism and ADRs. Research focusing on polymorphism of the cytochrome P450 system (CYPs) has become increasingly important and has highlighted the intra-and inter-individual responses to drug exposure. This system has recently been suggested to be an underlying candidate regarding the pathogenesis of ADRs in the oral mucous membrane. This review focuses on those CVDs reported to induce ODRs. In addition, it will provide data on specific drugs or drug classes, and outline and discuss recent research on possible mechanisms linking ADRs to drug metabolism patterns. Abbreviations used will be as follows:

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Adverse Drug Reactions to Cardiovascular Drugs

Torpet

Kragelund

Reibel

et al. 2004

Critical Reviews in Oral Biology & Medicine

View full text Add to dashboard Cite

show abstract

“… Symptomatic bradycardia: β-Blockers may be used in patients with asymptomatic, mild bradycardia, particularly when the heart rate increases with exercise [ 49 ]. The possibility of drug interactions that may lower the heart rate (e.g., digoxin and amiodarone) should also be considered [ 50 ]. Given the substantial benefits of β-blockers in HFrEF, asymptomatic bradycardia during β-blocker therapy is not a reason to discontinue it, and cardiac pacing should be considered on an individual basis [ 51 ].…”

Section: Optimizing the Use Of β-Blockers In Hfref: A Practical Approachmentioning

confidence: 99%

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction

Masarone

Martucci

Errigo

et al. 2021

JCDD

View full text Add to dashboard Cite

Treatment with β-blockers is the main strategy for managing patients with heart failure and reduced ejection fraction because of their ability to reverse the neurohumoral effects of the sympathetic nervous system, with consequent prognostic and symptomatic benefits. However, to date, they are underused, mainly because of the misconception that hypotension and bradycardia may worsen the haemodynamic status of patients with HFrEF and because of the presence of comorbidities falsely believed to be absolute contraindications to their use. To promote proper use of β-blockers in this article, we review the clinical pharmacology of β-blockers, the evidence of the beneficial effects of these drugs in heart failure with reduced ejection fraction, and the current guidelines for their use in clinical practice and in the presence of comorbidities (e.g., pulmonary disease, diabetes, atrial fibrillation, peripheral arterial disease, etc.). It is hoped that the practical approach discussed in this review will allow for a proper diffusion of knowledge about the correct use of β-blockers and the drug-disease interactions to achieve their increased use and titration, as well as for the selection of a specific agent with a view to a properly tailored approach for HFrEF patients.

show abstract

“…Class II AADs, more commonly called β-blockers, constitute a large and heterogeneous group of medications, all of which inhibit β-adrenergic receptors. 9 This review will focus on interactions involving commonly used agents, including bisoprolol, metoprolol, carvedilol, and propranolol.…”

Section: Classificationmentioning

confidence: 99%

Clinically Important Drug–Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants

Konieczny

Dorian

2019

J Innov Cardiac Rhythm Manage.

View full text Add to dashboard Cite

Until the last decade, vitamin K antagonists (VKAs) were the only agents available for oral anticoagulation. Although effective and accessible, their use was complicated by a narrow therapeutic window, the need for regular monitoring of the international normalized ratio, and an associated susceptibility to interactions with both food and numerous medications. Furthermore, the onset of action was delayed, often requiring bridging with intravenous agents. In more recent years, we have enjoyed the development of nonvitamin-K-dependent, direct oral anticoagulants (DOACs), which either directly inhibit the activity of factor IIa (eg, dabigatran) or factor Xa (eg, rivaroxaban, apixaban, edoxaban). These medications boast a more rapid onset of action, predictable pharmacokinetics, wider therapeutic window, and equal or superior safety profiles. Although these medications appear to have fewer drug-drug interactions than VKAs, their interactions remain of clinical importance, particularly in one of the largest populations requiring anticoagulation: patients with atrial fibrillation. These patients are rarely on single medications, with the majority of them requiring some form of rate or rhythm control due to their arrhythmia. Unfortunately, data on interactions between DOACs and antiarrhythmic medications, despite their common coadministration, remain limited. Here, we summarize the interactions between antiarrhythmics and VKAs and review existing knowledge regarding their interactions with DOACs.

show abstract

??-Blockers Drug Interactions of Clinical Significance

Cited by 19 publications

References 96 publications

Oral Adverse Drug Reactions to Cardiovascular Drugs

Oral Adverse Drug Reactions to Cardiovascular Drugs

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction

Clinically Important Drug–Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants

Contact Info

Product

Resources

About